REC 610
Alternative Names: REC-610; Recombinant shingles vaccine - Jiangsu Recbio TechnologyLatest Information Update: 13 Mar 2024
At a glance
- Originator Jiangsu Recbio Technology
- Class Synthetic vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Herpes zoster
Most Recent Events
- 06 Dec 2023 Jiangsu Recbio Technology completes a phase-I trial in Herpes zoster (Prevention) in Philippines (IM) (NCT05769049)
- 09 Feb 2023 Phase-I clinical trials in Herpes zoster (Prevention) in Philippines (IM) (NCT05769049)
- 19 Dec 2022 The Food and Drug Administration of the Philippines approves clinical trial application for REC 610 in Herpes zoster (Prevention)